NASDAQ: BIOA
Bioage Labs Inc Earnings Dates, Reports, Calls

Bioage Labs earnings were -$71.1M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest BIOA earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$21.1M, down 9.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BIOA reported annual earnings of -$71.1M, with 11.4% growth.

BIOA earnings history

Current Revenue
$0.0
Current Earnings
-$71.1M
Current Profit Margin
0%

BIOA Return on Equity

Current Company
-95%
Current Industry
12.5%
Current Market
34.1%
BIOA's Return on Equity (-95%)... subscribe to Premium to read more.
High Return on Equity Performance

BIOA undefined

Current Company
-37%
Current Industry
5.5%
BIOA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BIOA announces earnings.

BIOA undefined

Current Company
-20.8%
Current Industry
12%

BIOA vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BIOA-$68.57M-$71.11MN/A-$6.63
DERM-$8.40M-$14.67MN/A-$0.72
CGC-$292.60M-$326.16MN/A-$3.40
OGI-$27.75M-$36.52MN/A-$0.39
ESPR$7.57M-$51.75MN/A-$0.28

Bioage Labs Earnings Reports & History FAQ

What were Bioage Labs's earnings last quarter?

Bioage Labs (NASDAQ: BIOA) reported Q4 2024 earnings per share (EPS) of $15.13, up 220.75% year over year. Total BIOA earnings for the quarter were -$21.13 million. In the same quarter last year, Bioage Labs's earnings per share (EPS) was -$12.53.

If you're new to stock investing, here's how to buy Bioage Labs stock.

Is Bioage Labs profitable or losing money?

As of the last Bioage Labs earnings report, Bioage Labs is currently losing money. Bioage Labs's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$71.11 million, a 11.36% increase year over year.

What was BIOA's earnings growth in the past year?

As of Bioage Labs's earnings date in Q2 2025, Bioage Labs's earnings has grown year over year. BIOA earnings in the past year totalled -$71.11 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.